In this article for PharmaPhorum, Phastar’s Stephen Corson’s delves into the changing landscape of Health Technology Assessments (HTAs) in Europe. With the introduction of the EU-wide HTA regulation, there’s a shift towards a unified approach to evaluating new therapeutic products and medical devices. This change aims to harmonize and streamline the post-regulatory approval adoption process across European countries.
Read the full article in PharmaPhorum.